Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

8.86
-0.0200-0.23%
Post-market: 8.860.00000.00%16:10 EST
Volume:63.41K
Turnover:559.10K
Market Cap:154.96M
PE:-2.87
High:8.95
Open:8.77
Low:8.61
Close:8.88
52wk High:12.62
52wk Low:4.60
Shares:17.49M
Float Shares:11.81M
Volume Ratio:0.60
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0883
EPS(LYR):-4.2529
ROE:-60013.19%
ROA:-79.40%
PB:40.61
PE(LYR):-2.08

Loading ...

Elicio Therapeutics Grants 30,300 Inducement Stock Options Under 2024 Plan

Reuters
·
Feb 18

Elicio Therapeutics Reports Inducement Grants

GlobeNewswire
·
Feb 18

Elicio Therapeutics reports inducement grants

TIPRANKS
·
Jan 16

Elicio Therapeutics Grants Inducement Stock Options to New Employees

Reuters
·
Jan 16

Elicio Therapeutics Grants Stock Options to New Employees

Reuters
·
Dec 16, 2025

Elicio Therapeutics Reports Phase 2 Trial Shows ELI-002 7P Induces Broad Immune Response Beyond mKRAS

Reuters
·
Dec 11, 2025

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond Mkras in Ongoing Phase 2 Amplify-7P Trial

THOMSON REUTERS
·
Dec 11, 2025

Elicio Therapeutics appoints Marc Wolfgang as CTO

TIPRANKS
·
Nov 19, 2025

Press Release: Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Dow Jones
·
Nov 19, 2025

H.C. Wainwright Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)

TIPRANKS
·
Nov 19, 2025

JonesTrading Keeps Their Buy Rating on Elicio Therapeutics (ELTX)

TIPRANKS
·
Nov 14, 2025

Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate

Benzinga
·
Nov 14, 2025

Elicio Therapeutics Q3 net loss narrows, cash runway extended

Reuters
·
Nov 14, 2025

Elicio Therapeutics Reports Lower-Than-Projected Disease Progressions in Phase 2 AMPLIFY-7P Trial

Reuters
·
Nov 14, 2025

Elicio Therapeutics Q3 Basic EPS USD -0.6

THOMSON REUTERS
·
Nov 14, 2025

Elicio Therapeutics Q3 Income From Operations USD -8.045 Million

THOMSON REUTERS
·
Nov 14, 2025

Elicio Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Elicio Therapeutics Reports Robust T Cell Responses in Phase 2 Trial of ELI-002 7P for KRAS-Mutant Pancreatic Cancer

Reuters
·
Nov 07, 2025

Elicio Therapeutics Reports Robust, Cytolytic Mkras-Specific T Cell Responses Across Diverse Patient Hla in Ongoing Phase 2 Amplify-7P Trial of Eli-002 7P and New Eli-004 Preclinical Data at SITC

THOMSON REUTERS
·
Nov 07, 2025

Elicio Therapeutics Announces Late-Breaking Phase 2 Data on ELI-002 for Pancreatic Cancer at SITC 2025

Reuters
·
Nov 03, 2025